Your browser doesn't support javascript.
loading
Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease.
Koyun, Derya; Seval, Güldane Cengiz; Kircali, Ekin; Bozdag, Sinem Civriz; Toprak, Selami Koçak; Topçuoglu, Pervin; Özcan, Muhit; Arslan, Önder; Demirer, Taner; Ilhan, Osman; Beksaç, Meral; Gürman, Günhan; Yüksel, Meltem Kurt.
Afiliação
  • Koyun D; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Seval GC; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Kircali E; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Bozdag SC; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Toprak SK; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Topçuoglu P; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Özcan M; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Arslan Ö; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Demirer T; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Ilhan O; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Beksaç M; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Gürman G; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
  • Yüksel MK; Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
Indian J Hematol Blood Transfus ; 38(3): 601-605, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35747565
ABSTRACT
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, the results of five SR-aGVHD patients received AAT evaluated. Complete response was seen 2 of four patients with gastrointestinal (GI) aGVHD, partial response in one GI and one liver aGVHD. The overall response rate was 80%. AAT is an effective and safe treatment option in SR-aGVHD.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article